Harnessing AI and Quantum Computing for Revolutionizing Drug Discovery and Approval Processes: Case Example for...

Area of Science:

• Computational chemistry and pharmacology
• Drug discovery and development
• Bioinformatics and computational biology

Background:

• Traditional drug discovery is time-consuming and expensive, involving extensive laboratory and animal testing.
• Emerging technologies like artificial intelligence (AI) and quantum computing offer novel approaches to pharmaceutical research.
• The integration of computational methods, or in silico studies, is crucial for modernizing drug development.

Purpose of the Study:

• To demonstrate how computational models from digital computers, AI, and quantum computing can optimize drug discovery and approval.
• To highlight the potential of these technologies to reduce laboratory experiments, costs, and timelines in pharmaceutical development.
• To discuss the implications for regulatory processes and the future of drug development.

Main Methods:

• Review of 83 academic publications and interviews with pharmaceutical manufacturers.
• Application of AI for computational data analysis, including toxicity prediction of collagen as a case example.
• Utilizing in silico methods such as simulations, synthetic data generation, and data augmentation for drug discovery.

Main Results:

• Computational models can significantly reduce the need for in vitro and in vivo experiments.
• AI and quantum computing can accelerate the identification and assessment of potential drug candidates.
• In silico data generation and analysis are key to efficiently screening compound libraries and simulating biological interactions.

Conclusions:

• AI and quantum computing are poised to revolutionize drug discovery and approval processes.
• Computer-aided drug development, supported by in silico data, offers a more cost-effective and time-efficient approach.
• Regulatory bodies must adapt to integrate these advanced computational methods for streamlined drug development and market entry.